CT Lung Nodule Assessment

Assess lung nodules over time

Find similar products

Enables review and analysis of thoracic CT images, providing segmentation, quantification and characterization of physician-indicated lung nodules in a single study, or over the course of several prefetched thoracic studies. ​ The application can be used in both diagnostic and screening evaluations, supporting Low Dose CT Lung Cancer Screening(1).​ Offers a Prediction Risk Calculator(2)(3) tool based on patient and nodule characteristics for estimation of the probability that the lung nodules detected on baseline screening low-dose CT are malignant. Discreate results sharing (4) enables automatic transfer of structural results between the Workspace and reporting solutions, reducing reporting time and optimizing AV reporting workflow.

  • (1) The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or professional medical society. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011; 365:395-409) and subsequent literature, for further information.​ (2) Offered as separate commercial add-on.​ (3) These functionalities may not be available in all territories. Please contact a Philips representative for more details.​ (4) The integration of the solution is via IBE services or via customer home-grown solutions.

You are about to visit a Philips global content page

Continue

You are about to visit a Philips global content page

Continue

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

You are entering a Philips Healthcare Australia website
Please select the checkbox

The information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).

By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.